Venous thromboembolism in patients with cancer;Tromboembolia venosa en pacientes con cáncer

Medicina Clinica

Volumn 127, Issue 1, 2006, Pages 22-32

  Lecumberri, Ramón ^a   Feliu, Jesús ^a   Rocha, Eduardo ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CENTRAL VENOUS CATHETER; DISEASE ASSOCIATION; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; INCIDENCE; LONG TERM CARE; OCCULT CANCER; PROGNOSIS; PROPHYLAXIS; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 33746351497     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089866     Document Type: Review

References (142)

1. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988; 208:227-40.
2. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980;73:841-3.
3. Prandoni P, Lensing AW, Piccioli A, Bernardi E. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100:3484-8.
4. Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignacy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost. 1997;78:121-5.
5. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev. 1992;11:237-48.
6. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10:499-530.
7. Lee AYY, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137-45.
8. Falanga A, Rickles FR. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102:215-24.
9. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992;70:1194-201.
10. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine protease from malignant tissue. Biochemistry. 1985; 24:5558-67.
11. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16: 696t-701.
12. Silverstein MD, Heit JA, Mohr DN, Petersson TM, O'Fallon WM, Melton RJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-93.
13. Heit JA, Silverstein MD, Nohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-15.
14. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-9.
15. Baron JA, Gridley G, Weiderpassn E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077-80.
16. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-73.
17. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of the initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285-91.
18. Sorensen HT, Mellemjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343: 1846-50.
19. Samama M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 16:3415-20.
20. Goldhaber SZ, Tapson VF. DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259-62.
21. Kakkar AK, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg: is there a high risk group? Am J Surg. 1970; 120:527-30.
22. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg-vein thrombosis after major gynaecological surgery using labeled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw. 1974;81:311-6.
23. Rosenberg IL, Evans M, Pollok AV. Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or preoperative calf muscle stimulation: a controlled clinical trial. Br Med J. 1975;1:649.
24. Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg. 1983;70:172-4.
25. The Multicenter Trial Committee. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. J Am Med Assoc. 1984;251:2690-6.
26. Sue-Ling HM, Johnston D, McMahon MU, Philips PR, Davies JA. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. 1986;1:1173-6.
27. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992;127:310-3.
28. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism. Chest. 2004;126:338S-400S.
29. Agnelli G, Verso M. Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica. 2005;90:154-6.
30. Mandala M, Ferretti G, Cremonesi M, Cazzaniga M, Curigliano G, Barni S. Venous thromboembolism and cancer: new issues for an old topic. Critical Rev Oncol/Hematol. 2003;48:65-80.
31. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. A study of 159 patients. Cancer. 1984;54:1264-8.
32. Clahsen PC, Van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early brast cancer: an European Organization for Research and Treatment of Cancer Breast Cooperative Group Study. J Clin Oncol. 1994;12:1266-71.
33. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731-7.
34. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol. 1991;9:286-92.
35. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hrynuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:286-94.
36. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320:491-6.
37. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodel treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677-9.
38. Fisher B, Dignam J, Wolmark N, Mamounas E, Constantino J, Poller W, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Int. 1997;89:1673-82.
39. Tormey DC, Gray R, Taylor SG 4th, Knuiman M, Olson JE, Cummings FJ. Postoperative chemotherapy and chemohormonal therapy in women with node positive breast cancer. NCI Monog. 1986;1:75-80.
40. Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post-menopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999;17: 1988-98.
41. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson GG, et al. Tamoxifen versus placebo: double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monogr. 1986;1:119-23.
42. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockolm Breast Cancer Study Group. J Natl Cancer Inst. 1993;85:1398-406.
43. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med. 1989;320:479-84.
44. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. The Scottish Cancer trials Breast Group. BMJ. 1995;311:977-80.
45. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000; 18:2169-78.
46. Otten HMMB, Mathijssen J, Ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med. 2004;164:190-4.
47. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-5.
48. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol. 2002;20:1446-8.
49. Barbui T, Finazzi G, Grassi A, Marchioli T. Thrombosis in cancer patients treated with hematopoietic growth factor: a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75:368-71.
50. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost. 1999;25:147-55.
51. Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest. 1989;95:71-5.
52. Reichart P, Kretzschmar A, Biakhov M, Irvin D. A phase III double-blind placebo-controlled study evaluating the efficacy and safety of daily low-molecular weight heparin (dalteparina sodium, fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Annu Meet Am Soc Clin Oncol. 2002;21:1474.
53. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low dose warfarin for the prevention of central venous catheter-associated thrombosis in patient with cancer. J Clin Oncol. 2005;23:4063-9.
54. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol. 2002;20:3276-81.
55. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665-75.
56. Kuter DJ. Thrombotic complications of central venous catheter in cancer patients. The Oncologist. 2004;9:207-16.
57. Van Rooden CJ, Rosendaal FR, Barge RMY, Van Oostayen JA, Van der Meer FJ, Meinders AE, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol. 2003;123:507-12.
58. Schulman S, Lidmarker P, for the Duration of Anticoagulation Trial. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med. 2000;342:1953-8.
59. Taliani MR, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, et al, for the WODIT Investigators. Incidence of cancer after a first episode of idiophatic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost. 2003;1:1730-3.
60. Aderka D, Brown A, Zelikovsji A, Pinkhas J. Idiophatic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846-9.
61. Monreal M, Salvador R, Soriano V, Sabria M. Cancer and deep venous thrombosis. Arch Intern Med. 1988;148:485.
62. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer. 1991;67:541-5.
63. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-33.
64. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest. 1993;103:816-9.
65. Bastounis EA, Karyannakis AJ, Makri GG, Alexious D, Papalambrous EL. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med. 1996;239:153-6.
66. Ahmed Z, Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology. 1996;47:262-5.
67. Monreal M, Fernández-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in deep vein thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316-8.
68. Hettiarachchi RJK, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis. Cancer. 1998; 83:180-5.
69. Rance A, Emmerich J, Guedj C, Fiessinger JN. Occult cancer in patients with bilateral thrombosis. Lancet. 1997;350:1448-9.
70. Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, et al. The occurrence of subsequent Malignancy in patients with deep vein thrombosis. Results from a historical cohort study. Thromb Haemost. 1998;79:19-22.
71. Monreal M, Prandoni P. Venous thromboembolism and first manifestation of cancer. Semin Thromb Haemost. 1999;25:131-6.
72. Otten HM, Prins MH. Venous thromboembolism and occult maligancy. Thromb Res. 2001;102:V187-V94.
73. Bura A, Cailleux N, Bienvenu B, Leger P, Bissery A, Boccalon H, et al. Incidence of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients. J Thromb Haemost. 2004;2:441-4.
74. Piccioli A, Lensing AW, Prins MH, Falanga A, Scannapieco GL, Ieran M, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. The SOMIT Investigators Group. J Tromb Haemost. 2004;2:884-9.
75. Monreal M, Lensing AW, Prins MH, Bonet M, Fernández-Llamazares J, Muchart J, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004;2:876-81.
76. Büller HR. Has time come for screening for occult cancer in patients with venous thromboembolism? J Thromb Haemost. 2004;2:874-5.
77. Schutgens REG, Beckers MMJ, Haas FJLM, Biesma DH. The predictive value of D-dimer measurements of cancer in patients with deep vein thrombosis. Haematologica. 2005;90:214-9.
78. International Multicentre Trial. Prevention of fatal pulmonary embolism by low doses of heparin. Lancet. 1975;2:45-51.
79. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84: 1099-103.
80. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Grégoire RC, Taylor BM, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg. 2001;233:438-44.
81. Kakkar AK, Haas W, Walsh D, Nash G, Encke A. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery. Thromb Haemost. 2001;86 Suppl:OC1732.
82. Missmetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913-30.
83. Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost. 1990;16 Suppl:19-24.
84. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg. 1995;82:496-501.
85. Agnelli G, Bergqvist D, Cohen A. Randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparina in the prevention of venous thromboembolism aftger high-risk abdominal surgery: the PEGASUS Study. Blood. 2003;102:15.
86. Nurmohamed MT, Van Riel AM, Henkens CMA, Nurmohamed MM, Que GT, D'Azeman P, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost. 1996;75:223-38.
87. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism in neurosurgery. N Engl J Med. 1996;339:80-5.
88. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med. 2000;160:2327-32.
89. Agnelli G, Bolis G, Capusotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the Aristos project. J Thromb Haemost. 2003;Suppl:OC191.
90. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. The ENOXACAN II Investigators. N Engl J Med. 2002;346:975-80.
91. Rasmussen M. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged prophylaxis. Cancer Treat Review. 2002;28:141-4.
92. Rasmussen MS. Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery? Cancer Treat Review. 2003;29:15-7.
93. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in trombosis and cancer. J Thromb Haemost. 2003;1:1456-63.
94. Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2004;128:291-302.
95. Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Blood. 2002;100 Suppl:148a.
96. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Studiy (FAMOUS). J Clin Oncol. 2004;22:1944-8.
97. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomized trial of a very-low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-9.
98. Bern HM, Lokich JJ, Wallach SR, Bothe AJ, Benotti PN, Arkin CF, et al. Very low dose of warfarin can prevent trombosis in central venous catheters: a randomized, prospective trial. Ann Intern Med. 1990;112: 423-8.
99. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catéter trombosis. Intern Med J. 2002;32:84-8.
100. Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluoruracil-based chemotherapy? J Clin Oncol. 2003;21:736-9.
101. Monreal M, Alastrue A, Rull M, Mira X, Muxart H, Rosell R, et al. Upper extremity dep venous trombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75:251-3.
102. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paolett F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057-62.
103. Abdelkefi A, Othman TB, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost. 2004;92:654-61.
104. Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica. 2003;88:67-73.
105. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992; 326:1240-5.
106. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijsen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-83.
107. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-74.
108. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
109. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160:761-8.
110. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost. 1997;78:137-40.
111. Wester JP, De Valk HW, Nieuwenhuis HK, Brouwer CB, Van der Graaf Y, Meuwissen OJ, et al. Risk factor for bleeding during treatment of acute venous thromboembolism. Thromb Haemost. 1996;76:682-8.
112. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-13.
113. Rocha E, Panizo C, Lecumberri R. Tratamiento de la enfermedad tromboembólica venosa. Med Clin (Barc). 2000;115:224-35.
114. Rocha E, Martínez-González MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica. 2000;85: 935-42.
115. Koopman MMW, Prandomi P, Piovella F, Ockelford PA, Brandjes DP, Van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med. 1996;334:682-7.
116. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81.
117. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, et al, for the Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191-202.
118. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 337:657-62.
119. Ageno W, Grimwood R, Limbiati S, Dentali F, Steidl L, Wells PS. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 2005;90:220-4.
120. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for out patient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med. 1998;158:1809-12.
121. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998;158:2001-3.
122. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-15.
123. Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, et al. Use of inferior vena caval filtres and survival in patients with Malignancy. Cancer. 2004;101:1902-7.
124. Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17-I21.
125. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low-molecular-weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994;72:191-7.
126. Monreal M, Lafoz E, Olive A, Del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
127. Das SK, Cohen AT, Edmonson RA, Melissari E, Kakkar W. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20:521-7.
128. Lopaciuk S, Bielska-Falda H, Nosczyk W, Bielwiec M, Witkiewicz W, Filipecki S, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;81:26-31.
129. Gonzáles-Fajardo JA, Arreba E, Castrodeza J, Pérez JL, Fernández L, Agúndez I, et al. Venographic comparison of subcutaneous low molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999;30:283-92.
130. Veiga F, Escribá A, Maluenda MP, López Rubio M, Margalet I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000;84:559-64.
131. López-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martínez RVT, Lozano G, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001;33:77-90.
132. Hull RD, Pineo GF, Mah AF, Brant RF, for the LITE Study Investigators. Home-lite: safety and efficacy results for a study investigating the long term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. Thromb Haemost. 2001;Suppl:OC1647.
133. Kakkar VV, Gebska M, Kadziola Z, Roach C, Saba N, Manning A. Objective assessment of acute and long term treatment with unfractionated heparin and low molecular weight heparin in acute deep vein thrombosis. Thromb Haemost. 2003;89:764-80.
134. Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost. 2003;89:953-8.
135. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low molecular weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001;111: 130-9.
136. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism; meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1:1906-13.
137. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med. 2002;162: 1729-35.
138. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AJ, Prins M, et al, for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53.
139. Hull R, Pineo GF, Mah AF, Brant RF, for the LITE Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarina sodium in patients with current cancer. J Thromb Haemost. 2003;1:P373.
140. Deitcher SR, Kessler CM, Merli G, Rigas J, Lyons RM, Cort S. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparina sodium alone vs. initial enoxaparina sodium followed by warfarina for a 180-day period. J Thromb Haemost. 2003;1:OC194.
141. Monreal M, Zacharski L, Jiménez JA, Roncalés J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohor study. J Thromb Haemost. 2004;2:1311-5.
142. Buller HR, Agnelli G, Jull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. Chest. 2004; 126:401S-28S.